Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Significance of Matrix Metalloproteinase-9 (MMP-9) in Stage II Colorectal Carcinoma

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Approximately 30% of all colorectal cancer patients are diagnosed with stage II disease. Adjuvant therapy is not widely recommended. However, it is well-established that a subgroup of patients with stage II is at high risk for recurrence within their life time and should be considered for adjuvant chemotherapy. The present work was designed to assess the value of matrix metalloproteinase-9 (MMP-9) as a predictor of disease outcome in a series of 202 stage II colorectal cancer (CRC) patients with long-term follow-up.

Methods

The present study comprises a series of 202 patients who underwent bowel resection for stage II CRC at Turku University Hospital. Archival paraffin-embedded CRC tissue samples were used to prepare tissue microarray blocks for immunohistochemical staining with MMP-9 antibody.

Results

Forty-eight percent of all CRC samples were positive for MMP-9. There was no significant correlation between MMP-9 expression and age, depth of invasion, and lymph node status. However, MMP-9 expression was significantly related to histological grade (p = 0.03) and location of the tumor (p = 0.01), therefore, being lower in high-grade tumors and most intense in carcinomas of the descending colon and rectum. Tumors with high MMP-9 expression showed a higher recurrence rate than tumors with low expression (p = 0.02). MMP-9 negative tumors had a more favorable disease-free survival (DFS) than those expressing MMP-9 (p = 0.03). The same was true with disease-specific survival (DSS; p = 0.02) as well, high expression of MMP-9 being associated with shorter survival rates. In multivariate (Cox) survival analysis, MMP-9 expression proved to be an independent predictor of DFS, but not DSS, which was predicted by age and sex only.

Conclusion

Quantification of MMP-9 expression seems to provide valuable prognostic information in stage II CRC, particularly, in selecting the patients at high risk for recurrent disease who might benefit from adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough? Ann Oncol. 2003;14(7):1026–38.

    Article  CAS  PubMed  Google Scholar 

  2. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10(24):8229–34.

    Article  CAS  PubMed  Google Scholar 

  3. Herszenyi L, Farinati F, Cardin R, Istvan G, Molnar LD, Hritz I, et al. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19–9 in colorectal cancer. BMC Cancer. 2008;8:194.

    Article  PubMed  Google Scholar 

  4. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med. 1999;340(3):169–76.

    Article  CAS  PubMed  Google Scholar 

  5. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19. Epub 2004 Jun 3415.

    Article  PubMed  Google Scholar 

  6. Venook A. Status of adjuvant chemotherapy for stage II colon cancer, vol. 81. New Orleans, LA: ASCO Annual Meeting Publisher Book; 2004.

    Google Scholar 

  7. Elander N, Soderkvist P, Fransen K. Matrix metalloproteinase (MMP)-1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res. 2006;26(1B):791–79.

    CAS  PubMed  Google Scholar 

  8. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271(18):10672–80.

    Article  CAS  PubMed  Google Scholar 

  9. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, et al. Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol. 2007;13(5):676–82.

    CAS  PubMed  Google Scholar 

  10. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Li J, et al. Matrix metalloproteinase-9–1562C > T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol. 2007;13(34):4626–9.

    CAS  PubMed  Google Scholar 

  11. Herszenyi L, Sipos F, Galamb O, Solymosi N, Hritz I, Miheller P, et al. Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. Pathol Oncol Res. 2008;14(1):31–7. Epub 2008 Mar 2018.

    Article  CAS  PubMed  Google Scholar 

  12. Daniel P, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska O, Malecka-Panas E. Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. Int J Colorectal Dis. 2007;22(10):1165–72. Epub 2007 Mar 1130.

    Article  PubMed  Google Scholar 

  13. Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, Ismail T. Elevated serum matrix metalloproteinase-9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer. 2007;97(7):971–7. Epub 2007 Oct 2002.

    Article  CAS  PubMed  Google Scholar 

  14. Elzagheid A, Algars A, Bendardaf R, Lamlum H, Ristamaki R, Collan Y, et al. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol. 2006;12(27):4304–9.

    CAS  PubMed  Google Scholar 

  15. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.

    Article  CAS  PubMed  Google Scholar 

  16. Gorden DL, Fingleton B, Crawford HC, Jansen DE, Lepage M, Matrisian LM. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer. 2007;121(3):495–500.

    Article  CAS  PubMed  Google Scholar 

  17. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene. 1992;7(1):77–83.

    CAS  PubMed  Google Scholar 

  18. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 1999;20(5):749–55.

    Article  CAS  PubMed  Google Scholar 

  19. Legrand C, Gilles C, Zahm JM, Polette M, Buisson AC, Kaplan H, et al. Airway epithelial cell migration dynamics. MMP-9 role in cell-extracellular matrix remodeling. J Cell Biol. 1999;146(2):517–29.

    Article  CAS  PubMed  Google Scholar 

  20. Niu J, Gu X, Turton J, Meldrum C, Howard EW, Agrez M. Integrin-mediated signalling of gelatinase B secretion in colon cancer cells. Biochem Biophys Res Commun. 1998;249(1):287–91.

    Article  CAS  PubMed  Google Scholar 

  21. Cho YB, Lee WY, Song SY, Shin HJ, Yun SH, Chun HK. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol. 2007;38(11):1603–10. Epub 2007 Jul 1631.

    Article  CAS  PubMed  Google Scholar 

  22. Gervaz P, Bouzourene H, Cerottini JP, Chaubert P, Benhattar J, Secic M, et al. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum. 2001;44(3):364–72. discussion 372-363.

    Article  CAS  PubMed  Google Scholar 

  23. Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, Laurberg S, Laiho P, Aaltonen LA, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut. 2005;54(3):374–84.

    Article  CAS  PubMed  Google Scholar 

  24. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121(4):714–23.

    Article  CAS  PubMed  Google Scholar 

  25. Hilska M, Collan YU, OL VJ, Kossi J, Hirsimaki P, Laato M, et al. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum. 2005;48(12):2197–208.

    Article  PubMed  Google Scholar 

  26. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996;14(12):3133–40.

    CAS  PubMed  Google Scholar 

  27. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer. 1996;74(3):413–7.

    CAS  PubMed  Google Scholar 

  28. Sutnar A, Pesta M, Liska V, Treska V, Skalicky T, Kormunda S, et al. Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour Biol. 2007;28(5):247–52. Epub 2007 Nov 2009.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Radiotherapy, Turku University Hospital, University of Turku, Turku, Finland

    Abdelbaset Buhmeida, Riyad Bendardaf, Kari Syrjänen & Seppo Pyrhönen

  2. Department of Surgery, Turku University Hospital, University of Turku, Turku, Finland

    Marja Hilska & Matti Laato

  3. Department of Pathology, Turku University Hospital, University of Turku, Turku, Finland

    Yrjö Collan

  4. Department of Oral Pathology, Turku University Hospital, University of Turku, Turku, Finland

    Stina Syrjänen

  5. Department of Oncology and Radiotherapy, Turku University Hospital, P.O. Box 52, Savitehtaankatu 1, 20521, Turku, Finland

    Abdelbaset Buhmeida

Authors
  1. Abdelbaset Buhmeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riyad Bendardaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marja Hilska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yrjö Collan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matti Laato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stina Syrjänen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kari Syrjänen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seppo Pyrhönen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdelbaset Buhmeida.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buhmeida, A., Bendardaf, R., Hilska, M. et al. Prognostic Significance of Matrix Metalloproteinase-9 (MMP-9) in Stage II Colorectal Carcinoma. J Gastrointest Canc 40, 91–97 (2009). https://doi.org/10.1007/s12029-009-9091-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-009-9091-x

Keywords

Search

Navigation